SCHEMBL8231799

SCHEMBL8231799

CC(CO)c1ccc(CC(=O)NC(C)c2ccc(OCC(F)(F)F)cn2)cc1

nearest known ligand 0.83

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CACNA1I Q9P0X4 6/20 0.83
CACNA1G O43497 4/20 0.83
CACNA1H O95180 4/20 0.83
CNR2 P34972 2/20 0.83
KCNH2 Q12809 1/20 0.83
HTT P42858 1/20 0.44
KMT2A Q03164 1/20 0.42
ALDH1A1 P00352 3/20 0.42
SLC22A12 Q96S37 1/20 0.40
CYP2C9 P11712 2/20 0.39
CYP2C19 P33261 2/20 0.39
KDM4E B2RXH2 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
IDH1 O75874 2/20 0.38
ACACB O00763 1/20 0.38
MAPT P10636 1/20 0.37
HPGD P15428 1/20 0.37
CYP17A1 P05093 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1064366 1.00 CACNA1I (0.83) CACNA1ICACNA1GCACNA1HCNR2KCNH2
Suvecaltamide SCHEMBL21828396 0.91 CACNA1I (1.00) CACNA1ICACNA1GCACNA1HCNR2KCNH2
Suvecaltamide SCHEMBL1065999 0.91 CACNA1I (1.00) CACNA1ICACNA1GCACNA1HCNR2KCNH2
Suvecaltamide SCHEMBL29791943 0.91 CACNA1I (1.00) CACNA1ICACNA1GCACNA1HCNR2KCNH2
SCHEMBL1058794 0.88 CACNA1I (0.83) CACNA1ICACNA1GCACNA1HCNR2KCNH2
SCHEMBL8231358 0.88 CACNA1I (0.83) CACNA1ICACNA1GCACNA1HCNR2KCNH2
SCHEMBL1060457 0.87 CACNA1I (0.82) CACNA1ICACNA1GCACNA1HCNR2KCNH2
SCHEMBL1062188 0.86 CACNA1I (0.80) CACNA1ICACNA1GCACNA1HCNR2KCNH2
SCHEMBL1060490 0.86 CACNA1I (0.80) CACNA1ICACNA1GCACNA1HCNR2KCNH2
SCHEMBL1062749 0.86 CNR2 (0.80) CACNA1ICACNA1GCACNA1HCNR2KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020072773-A9 TREATING ESSENTIAL TREMOR USING (R)-2-(4-ISOPROPYLPHENYL)-N-(1-(5-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-2-YL)ETHYL)ACETAMIDE CAVION, INC. (US) 2020-07-16 WO disclosed
US-8263627-B2 Pyridyl amide T-type calcium channel antagonists MERCK SHARP & DOHME CORP. (US) 2012-09-11 US disclosed
US-20110112064-A1 Pyridyl Amide T-Type Calcium Channel Antagonists MERCK SHARP & DOHME CORP. (US) 2011-05-12 US disclosed
US-7875636-B2 2-(4-isopropenylphenyl)-N-[(1R)-1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl]acetamide; epilepsy, pain, neuropathic pain, schizophrenia, Parkinson's disease, depression, anxiety, sleep disorders, psychosis, schizophrenia, cardiac arrhythmia and hypertension MERCK SHARP & DOHME CORP. (US) 2011-01-25 US disclosed
US-20090275550-A1 Pyridyl Amide T-Type Calcium Channel Antagonists MERCK SHARP & DOHME LLC 2009-11-05 US disclosed
WO-2007120729-A2 PYRIDYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS MERCK & CO., INC. (US) 2007-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112064-A1 Pyridyl Amide T-Type Calcium Channel Antagonists CACNA1G, CACNA1H, CACNA1I CACNA1I 3/4885CACNA1G 1/4885CACNA1H 2/4885
US-20090275550-A1 Pyridyl Amide T-Type Calcium Channel Antagonists CACNA1G, CACNA1H, CACNA1I CACNA1I 3/4885CACNA1G 1/4885CACNA1H 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.